Azienda Ospedaliero-Universitaria Policlinico Sant'Orsola-Malpighi di Bologna, Bologna, Italy.
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy.
Future Oncol. 2020 Jan;16(1s):5-8. doi: 10.2217/fon-2019-0595. Epub 2019 Dec 24.
Retroperitoneal sarcomas are extremely rare malignant tumors. The most common type of sarcomas arising in the retroperitoneum are liposarcomas, occurring mostly in the sixth and seventh decades of life. The only potentially curative approach to liposarcomas is the complete surgical resection of the tumor with negative microscopic margins. However, retroperitoneal liposarcomas exhibit a propensity for local recurrence and distant metastasis despite the negative surgical margins, thus requiring additional therapy. Eribulin demonstrated a benefit in terms of overall survival in patients with advanced or metastatic liposarcoma. We report two cases of patients, both submitted to concomitant right nephrectomy, who experienced a long-lasting control of recurrent retroperitoneal liposarcoma before being submitted to eribulin-based therapeutic regimens (23 and 24 treatment cycles completed, respectively).
腹膜后肉瘤极为罕见,是一种恶性肿瘤。最常见的腹膜后肉瘤是脂肪肉瘤,多发生于六七十岁。唯一可能治愈的方法是完整切除肿瘤并保证显微镜下切缘阴性。然而,尽管手术切缘阴性,腹膜后脂肪肉瘤仍有局部复发和远处转移的倾向,因此需要额外的治疗。在晚期或转移性脂肪肉瘤患者中,艾瑞布林在总生存期方面显示出获益。我们报告了两例患者,他们都接受了同期右肾切除术,在接受艾瑞布林治疗方案(分别完成了 23 个和 24 个治疗周期)之前,复发性腹膜后脂肪肉瘤得到了长时间的控制。